

P Barton Duell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10018346/publications.pdf>

Version: 2024-02-01

64
papers

2,589
citations

361045

20
h-index

205818

48
g-index

64
all docs

64
docs citations

64
times ranked

2467
citing authors

#	ARTICLE	IF	CITATIONS
1	Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, e38-e81.	1.1	431
2	Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1780.	3.8	314
3	Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, ATV000000000000147.	1.1	207
4	Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States. <i>Circulation: Cardiovascular Genetics</i> , 2016, 9, 240-249.	5.1	170
5	Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 101161ATV000000000000153.	1.1	167
6	Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. <i>JAMA Cardiology</i> , 2020, 5, 1124.	3.0	128
7	Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia. <i>Journal of the American Heart Association</i> , 2019, 8, e013225.	1.6	114
8	PCSK9 Association With Lipoprotein(a). <i>Circulation Research</i> , 2016, 119, 29-35.	2.0	99
9	Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1169-1178.	0.6	83
10	Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. <i>Journal of Clinical Lipidology</i> , 2020, 14, 649-659.e6.	0.6	70
11	Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2020, 14, 398-413.	0.6	70
12	Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry. <i>Atherosclerosis</i> , 2017, 267, 19-26.	0.4	64
13	Application of PCSK9 Inhibitors in Practice. <i>Circulation Research</i> , 2019, 124, 32-37.	2.0	61
14	Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry. <i>Atherosclerosis</i> , 2019, 289, 85-93.	0.4	60
15	US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1223-1229.	0.6	57
16	Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 868-880.	2.2	38
17	Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, e157-e174.	0.8	37
18	Management of dyslipidemia in adult solid organ transplant recipients. <i>Journal of Clinical Lipidology</i> , 2019, 13, 231-245.	0.6	36

#	ARTICLE	IF	CITATIONS
19	Prevention of Atherosclerosis with Dietary Antioxidants: Fact or Fiction?. <i>Journal of Nutrition</i> , 1996, 126, 1067S-1071S.	1.3	30
20	Application of PCSK9 Inhibitors in Practice. <i>Circulation Research</i> , 2017, 121, 499-501.	2.0	26
21	Prevalence of Cerebrotendinous Xanthomatosis Among Patients Diagnosed With Acquired Juvenile-Onset Idiopathic Bilateral Cataracts. <i>JAMA Ophthalmology</i> , 2019, 137, 1312.	1.4	23
22	Chylomicronemia syndrome: Familial or not?. <i>Journal of Clinical Lipidology</i> , 2020, 14, 201-206.	0.6	21
23	Prevention of atherosclerotic cardiovascular disease in South Asians in the US: A clinical perspective from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2021, 15, 402-422.	0.6	20
24	Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. <i>Journal of Clinical Lipidology</i> , 2022, 16, 286-297.	0.6	20
25	Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India. <i>Journal of Clinical Lipidology</i> , 2020, 14, e1-e13.	0.6	17
26	Real-world utilization of bempedoic acid in an academic preventive cardiology practice. <i>Journal of Clinical Lipidology</i> , 2022, 16, 94-103.	0.6	16
27	Short-term folic acid supplementation induces variable and paradoxical changes in plasma homocyst(e)ine concentrations. <i>Lipids</i> , 2001, 36, S27-S32.	0.7	14
28	Update on cerebrotendinous xanthomatosis. <i>Current Opinion in Lipidology</i> , 2021, 32, 123-131.	1.2	14
29	Metabolic profiling in serum, cerebrospinal fluid, and brain of patients with cerebrotendinous xanthomatosis. <i>Journal of Lipid Research</i> , 2021, 62, 100078.	2.0	14
30	Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol. <i>American Journal of Preventive Cardiology</i> , 2020, 1, 100012.	1.3	13
31	Children with Heterozygous Familial Hypercholesterolemia in the United States: Data from the Cascade Screening for Awareness and Detection-FH Registry. <i>Journal of Pediatrics</i> , 2021, 229, 70-77.	0.9	13
32	Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1437-1449.	1.2	13
33	Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients. <i>JACC: Case Reports</i> , 2020, 2, 396-399.	0.3	12
34	Cerebrotendinous xanthomatosis without neurological involvement. <i>Journal of Internal Medicine</i> , 2021, 290, 1039-1047.	2.7	12
35	Molecular Characterization of Familial Hypercholesterolemia in a North American Cohort. <i>Journal of the Endocrine Society</i> , 2020, 4, bvz015.	0.1	10
36	Diagnosis of Familial Hypercholesterolemia: Table 1. <i>American Journal of Clinical Pathology</i> , 2016, 145, 437-439.	0.4	8

#	ARTICLE	IF	CITATIONS
37	Mustard oil and cardiovascular health: Why the controversy?. Journal of Clinical Lipidology, 2022, 16, 13-22.	0.6	8
38	Evidence for intensive LDL-C lowering for acute coronary syndrome: Recommendations from the Lipid Association of India. Journal of Clinical Lipidology, 2022, 16, 261-271.	0.6	8
39	The extent of familial hypercholesterolemia instruction in US schools and colleges of medicine, pharmacy, and osteopathic medicine. Journal of Clinical Lipidology, 2015, 9, 281-288.	0.6	7
40	Reduced psychological distress in familial chylomicronemia syndrome after patient support group intervention. Journal of Clinical Lipidology, 2018, 12, 240-242.	0.6	7
41	Real-world utilization of pharmacotherapy with new evidence-based cardiovascular indications in an academic preventive cardiology practice. American Journal of Preventive Cardiology, 2021, 5, 100144.	1.3	7
42	Evinacumab for treatment of familial hypercholesterolemia. Expert Review of Cardiovascular Therapy, 2021, 19, 739-751.	0.6	6
43	Hypertriglyceridemia. , 1992, 2, 321-331.		5
44	Modern Management of Familial Hypercholesterolemia. Metabolic Syndrome and Related Disorders, 2016, 14, 463-467.	0.5	5
45	JCL Roundtable: Lipid clinic operations. Journal of Clinical Lipidology, 2019, 13, 511-521.	0.6	5
46	Severe respiratory failure in a patient with COVID-19 and acromegaly: rapid improvement after adding octreotide. BMJ Case Reports, 2021, 14, e243900.	0.2	5
47	Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: A collaborative clinical practice statement. American Journal of Preventive Cardiology, 2021, 6, 100183.	1.3	4
48	Apolipoprotein B as a Predictor of CVD. Journal of the Association of Physicians of India, The, 2020, 68, 50-53.	0.0	4
49	The epidemic of atherosclerotic cardiovascular disease in India. Journal of Clinical Lipidology, 2020, 14, 170-172.	0.6	3
50	Triglycerides and Atherosclerotic Cardiovascular Disease. Journal of the Association of Physicians of India, The, 2020, 68, 35-41.	0.0	3
51	Aggressive Treatment for Severe Forms of Familial Hypercholesterolemia. Journal of the American College of Cardiology, 2020, 75, 575-577.	1.2	2
52	Cerebrotendinous xanthomatosis, sitosterolemia, Smith-Lemli-Opitz syndrome and the seminal contributions of Gerald Salen, MD (1935â€“2020). Journal of Clinical Lipidology, 2021, 15, 540-544.	0.6	2
53	When is it Appropriate to Lower Low Density Lipoprotein-Cholesterol Levels to < 30 mg/dL?. American Journal of Cardiology, 2021, 157, 142-144.	0.7	1
54	Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2021, 19, .	0.8	1

#	ARTICLE	IF	CITATIONS
55	Pelacarsen. Antisense oligonucleotide targeting apolipoprotein(a), Treatment of lipoprotein disorders, Treatment of cardiovascular diseases. <i>Drugs of the Future</i> , 2022, 47, 11-25.	0.0	1
56	Lipid Association of India Expert Consensus Statement on Management of Dyslipidemia in Indians 2020: Part III. <i>Journal of the Association of Physicians of India, The</i> , 2020, 68, 8-9.	0.0	1
57	Lifestyle Modification in the Prevention of Atherosclerotic Cardiovascular Disease. <i>Journal of the Association of Physicians of India, The</i> , 2020, 68, 10-20.	0.0	1
58	High Sensitivity C-Reactive Protein. <i>Journal of the Association of Physicians of India, The</i> , 2020, 68, 47-49.	0.0	1
59	Acute Pancreatitis Due to Hyperchylomicronemia. <i>Contemporary Endocrinology</i> , 2021, , 257-275.	0.3	0
60	Aprocitan. Dual endothelin ETA/ETB receptor antagonist, Treatment of resistant hypertension. <i>Drugs of the Future</i> , 2021, 46, 595.	0.0	0
61	Use of commercial genetic testing to help reclassify LDL receptor variants in clinical practice: A case report. <i>Journal of Clinical Lipidology</i> , 2021, 15, 447-450.	0.6	0
62	Low Density Lipoprotein Cholesterol Targets in Secondary Prevention of Atherosclerotic Cardiovascular Disease. <i>Journal of the Association of Physicians of India, The</i> , 2020, 68, 21-34.	0.0	0
63	Lipoprotein(a) and ASCVD risk. <i>Journal of the Association of Physicians of India, The</i> , 2020, 68, 42-46.	0.0	0
64	Non-HDL Cholesterol and Atherosclerotic Cardiovascular Disease. <i>Journal of the Association of Physicians of India, The</i> , 2020, 68, 54-58.	0.0	0